Small David H, Losic Dusan, Martin Lisandra L, Turner Bradley J, Friedhuber Anna, Aguilar Marie-Isabel
Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia.
IUBMB Life. 2004 Apr;56(4):203-8. doi: 10.1080/15216540410001709211.
Abnormal proteinaceous deposits are found in the brain of patients with many different neurodegenerative diseases. In many of these diseases, the production of the deposits is probably associated with disease pathogenesis. In Alzheimer's disease (AD), the amyloid protein (A beta), is produced by the action of enzymes known as secretases, which cleave the beta-amyloid protein precursor. A beta is secreted from cells in the brain, after which it oligomerizes and is deposited in the extracellular compartment of the brain to form amyloid plaques and amyloid angiopathy. Targeting the production of A beta and its aggregation is now a key strategy in the development of novel therapeutic agents for the treatment of AD. This review examines the potential of immunization strategies, cholesterol-lowering drugs, protease inhibitors and nicotinic drugs for the treatment of AD.
在许多不同神经退行性疾病患者的大脑中发现了异常蛋白质沉积物。在这些疾病中的许多情况下，沉积物的产生可能与疾病发病机制有关。在阿尔茨海默病（AD）中，淀粉样蛋白（Aβ）是由称为分泌酶的酶作用产生的，这些酶切割β-淀粉样蛋白前体。Aβ从大脑中的细胞分泌出来，然后寡聚化并沉积在大脑的细胞外区域，形成淀粉样斑块和淀粉样血管病。针对Aβ的产生及其聚集现在是开发治疗AD新型治疗药物的关键策略。这篇综述探讨了免疫策略、降胆固醇药物、蛋白酶抑制剂和烟碱类药物治疗AD的潜力。
